TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Bio, Inc. (TELA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 9.74 M | -5,649,000 | 59.17 M | 78.05 M | 71.73 M |
| 2022 | 6.62 M | -2,103,000 | 53.55 M | 67.86 M | 62.45 M |
| 2021 | 4.23 M | -12,440,000 | 42.45 M | 62.54 M | 59.06 M |
| 2020 | 2.68 M | -43,567,000 | 37.43 M | 86.46 M | 83.23 M |
| 2019 | 2.84 M | -15,059,000 | 36.96 M | 67.92 M | 64.33 M |